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Development of a self-reporting questionnaire, BURMIG, to
evaluate the burden of migraine
Abstract
We developed a 77-item self-reporting questionnaire to assess the burden of migraine (BURMIG),
including headache characteristics, migraine associated disability, comorbidities, management, and the
consequences on the patients' lives. We translated BURMIG into four languages (French, Portuguese,
German and English) and tested it in 130 headache patients (20 pain clinic, 17 primary care and 93
general public) in Luxembourg. We performed a linguistic and a face-content validation and tested the
questionnaire for its comprehensiveness, internal consistency and for its retest-reliability at an interval
of 1 month (completion rates were 79.6 and 76.4%, for test and retest, respectively). Retest-reliability
for the different parts of the questionnaire varied between 0.6 and 1.0 (Kappa coefficient), with an
intracorrelation coefficient of 0.7-1.0. The internal consistency was between 0.74 and 0.91 (Cronbach's
alpha). The questionnaire BURMIG is suitable to evaluate the burden of migraine and can be used in
English, German, French and Portuguese.
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Introduction  
Migraine is a common and disabling neurobiological disorder [1] which is under-recognized and under-treated [2, 3]. 
It imposes a substantial health burden with nearly all migraine sufferers experiencing impairment of social activities 
and of work capacity [4, 5]. The World Health Report 2002 [3] ranks migraine as number 12 in women and number 
19 in both genders amongst all causes of disability in the world. In spite of this, it is estimated that only about 50% of 
migraine patients are diagnosed and, therefore, treated adequately [6–10]. There are a few validated questionnaires 
such as the ID migraine to diagnose migraine, and the migraine disability assessment score (MIDAS) to assess 
disability in the last 3 months, but there is no comprehensive questionnaire to assess migraine associated burden.  
The physical and emotional impact of migraine on individual sufferers, their caretakers, family and colleagues is 
poorly acknowledged and this is true as well for the social and economic burden of migraine on society in 
comparison with those of other less prevalent, neurological disorders [9, 11–13].  
We aimed to develop and validate a questionnaire to assess the burden of migraine after having translated it into 
the main languages in order to use it in subsequent studies in different linguistic populations.  
Questionnaire  
We designed a questionnaire combining elements from established questionnaires and added further questions 
concerned with disease management and social consequences of headache. Priority areas for the questionnaire were 
defined with joint support from NGO’S (Swiss Migraine Trust Foundation, Migraine Action Association UK, 
Switzerland and Luxembourg), several international headache experts (see ‘‘Acknowledgements’’) and the 
Luxembourg Ministry of Health. Ethics committee approval for the study was obtained from the National Ethic and 
Research Board of Luxembourg.  
The resulting questionnaire contains 77 items, 17% of them are open questions. In the first part, the respondents 
are asked for biographical details such as age, gender, their most spoken language and their employment status. For 
the purpose of migraine diagnosis, the questions from ‘‘ID migraine’’ [14] are included. Specific information on 
headache, such as age of onset, the average number of headache days per month for the last 3 months, and symptoms 
before and after the headaches are gathered as well as information on general health, and previous and current 
disorders using items from the World Health Organization Disability Assessment Schedule II (WHODAS II) [15], 
the Migraine Disability Assessment Scale (MIDAS) [16] and the Patient Health Questionnaire-9 (PHQ-9) [17]. 
Participants are asked about the influence of headaches on their job and family-life as well as whether they ever had 
consulted medical doctors, about the diagnosis that was made and about the medication that had been prescribed. 
Psychosocial circumstances having worsened the headaches, limitations in social activities, conceptions of headache 
and the need of support from health professionals to improve the headaches are also assessed.  
Evaluation of the questionnaire  
The testing of the questionnaire included face, content, and language validity; the stability of the questionnaire over 1 
month, a period of time during which little or no change is expected (Test–retest reliability); the extent to which the 
questionnaire is able to discriminate between respondents with more or less severe disease status (construct validity) 
and the extent to which individual items in a questionnaire correlate with other items relating to the particular area of 
investigation (internal consistency). The respective methodology is detailed below.  
Study population  
Patients with headache were recruited from primary care centres, pain clinics and lay organisations. The idea behind 
this recruitment was to test the questionnaire in different settings. Selection for the primary care setting was done by 
doctors in general practice from the personal acquaintance of the project team. For the pain clinic setting the patients 
were selected from the pain clinic of the Centre Hospitalier de Luxembourg (Central Hospital in Luxembourg). 
When consulting because of headaches, both of these patient groups were asked by their physician to complete the 
questionnaire. For a third group of headache patients, headache sufferers with different employment settings were 
consecutively recruited by the national occupational health service and by a patient organisation.  
The samples size needed to investigate internal consistency, construct validity and for test–retest reliability was 
estimated by using the kappa formula (see below). Assuming an absolute precision of 0.18 (given the validated parts 
of the questionnaire), we estimated that 73 responses to the main questions in the second test would enable a Kappa 
value of C0.5 to be detected with a power of 0.95 (two-tailed a = 0.05). Thus allowing for a 60% response rate, 135 
subjects were considered necessary.  
Face, content and language validity  
Initial content validity was explored through systematic review by experts, and face validity was tested by pre-
piloting with 23 volunteers. All questions which had not been used before in the respective language in validated 
questionnaires were translated using a forward–backward method with two different native translators. Comprehen-
siveness was piloted with native speaker volunteers.  
Test–retest reliability  
Questions were categorized by the amount of change expected, as described previously for the development of a 
comparable questionnaire [18], primarily based on the time frame of the question and blinded to the results as 
follows: ‘no change expected,’ ‘change unlikely,’ ‘1 unit change expected,’ ‘3 unit change expected,’ ‘change 
likely’.  
The data from the two periods of answering the questionnaire were compared to assess test–retest reliability. For 
categorical data, this was estimated by using agreement measures as percentage agreement, Kappa values, Mac Ne-
mar’s S test and Bowker’s S test. Percentage agreement gives an estimate of within-patient agreement. The Kappa 
coefficient indicates when the observed agreement exceeds chance-agreement; a value above 0.6 is generally 
considered as acceptable. The Mac Nemar’s S provide a measure of agreement when used between two measures of 
the same questionnaire in the same patient. The null hypothesis of the Bowker’s S test is that the probabilities of cells 
in the square table satisfy symmetry. It was used for r 9 c tables where r [ 2or c [ 2. For the questions with discrete 
integer data, intraclass correlation coefficient (ICC) was calculated using a 2-way random effects model for 
agreement.  
Construct validity  
Comparisons between these samples were made for the total scores of the WHODASII, MIDAS and PHQ9. 
Comparison between categorical scores of the three samples was performed by using a chi-square test. Continuous 
values of the scores were also used for comparison and a one-way ANOVA was used with the score as dependent 
variable. Normality was assessed with a Kolmogorov– Smirnov test; if significant, data were log-transformed and 
analysed if normally distributed. Otherwise, the Kruskall– Wallis test was used.  
Internal consistency/content  
Where appropriate, cross-tabulations were used to check for internal consistency. Blocks of questions corresponding 
to ID, WHODASII, MIDAS and PH9 were compared in terms of correlations.  
This was done in order to verify if they measure the same construct in a multilingual context and in the newly 
designed questionnaire. The Cronbach’s alpha coefficient was used to explore the overall consistency of the ID, 
WHODAS II, MIDAS and PHQ-9 questionnaires. The larger the overall alpha coefficient, the more likely that items 
contribute to a reliable scale. A value of 0.70 suggests an acceptable reliability coefficient; smaller reliability 
coefficients are seen as inadequate. A coefficient alpha after deleting each variable independently from the scale was 
calculated to determine how each item reflects the reliability of the scale. When the coefficient increases after an item 
is deleted from the scale, one can assume that the item is not correlated highly with other items in the scale. 
Conversely, if the coefficient decreases, it can be assumed that the item is highly correlated with other items in the 
scale.  
Results  
Population and frequency of headache in the samples  
A total of 130 questionnaires were completed leading to a response rate of 65% (Fig 1). Out of this sample, 15.4%  
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Fig. 1 Tests and samples used in the different steps of the BURMIG questionnaire validation  
(n = 20) were from the pain clinic, 13.1% (n = 17) from the primary care centre and 71.5% (n = 93) from the lay 
organisation (Table 1). Fifty-two persons (40%) responded in German, 1 (0.8%) in English, 72 (55.4%) in French 
and 5 (3.8%) in Portuguese. Eighty-four percent were women, mean age was 41.9 ± 11.5, the gender distribution was 
significantly different (P = 0.03) between centres. There was no statistically significant difference in age, age at onset 
of headaches, work status and diagnosis of migraine between the three groups. Headache frequencies were unequal 
between centres (P = 0.02) with higher headache frequencies in subjects at the pain clinic. In the primary care 
setting, most individuals were in the 4–9 days/month category. In the pain clinic, most of the patients had headache 
on C15 days/month. The general public population had a similar profile as the primary care setting.  
Out of 130 subjects of the whole population, 28 did not answer all the MIDAS questions leading to the unfeasi-
bility to calculation of the total score. Thus, 102 subjects only had the total score. When re-running the comparison 
without the unhealthy subjects, only 10 subjects out the 28 had no total scores. Forty-nine subjects had the total 
score.  
Completion rates  
Completion rates for the items of the questionnaire varied between 5.83 and 100.00%. As the questionnaire included 
some questions with more than one possible choice or subquestions, only the principal item was kept to evaluate  
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  Primary care  Pain clinic  General public  All  P value 
Age  Year (mean ± SD)  38 ± 13  39 ± 10  43 ± 11  41 ± 11  0.14  
Gender  M/F (%)  0/100  30/70  16/84  16/84  0.03  
Work status  Economic workers (%)  70  75  73  73  0.95  
Diagnosis Headache 
frequency  
Migraine days/month (%) \1 
(%)  88 0  70 0  76 2  77 2  
0.45  
 1–3 (%)  29  30  21  24   
 4–9 (%)  35  10  45  38   
Age of onset  
10–14 (%) [15 (%) Year 
(mean ± SD)  
18 18 24 ± 10  15 45 20 ± 11  19 12 20 ± 10  18 18 20 ± 
10  
0.02 
0.36  
 
questions with good completion rates. Thus, 63% questions were found to have completions rates of 90% or more. 
Questions where there were several choices tended to have completion rates around 10%. There was no difference 
for completion rates between genders and language groups. Completion rates of the second questionnaire varied 
from  
5.41 to 100% and were very similar to the first questionnaire (63% of questions with completion C90%).  
Test–retest reliability  
Out of the 130 subjects recruited for the validation process, 91 subjects replied a second time to the questionnaire 
sent 1 month later. Seventy-nine single items (including subquestions) were used to assess reliability, excluding open 
questions; 67.1% of the items (n = 53) were over an 80% agreement, whereas 13.9% (n = 11) ranged between 60 and 
80% and 19% (n = 15) were below a 60% agreement.  
The Kappa coefficient ranged from 0.23 to 0.99. Questions categorized as ‘no change expected’ (0.86–0.99) and 
‘change unlikely’ (0.68–0.99) showed a good agreement (Table 2). From the items categorized as ‘1 unit change 
expected’ or ‘3 unit change expected’ the kappa showed values ranging from 0.45 to 0.92, indicating a poor 
agreement for some questions; unsurprisingly, from the items categorized as ‘change likely’ the kappa value showed 
lower values ranging from 0.23 to 0.77. Questions, which showed the smallest agreement, were the items from the 
WHODAS II, PHQ9 and questions 5 and 6 from the MIDAS.  
Mac Nemar’s S test showed no significant differences. Only one item was significant (P = 0.03) with the Bow-
ker’s S test: No agreement was observed for ‘Feeling tired or having little energy’ from the question 25 (PHQ9) 
between the two measures. The intra-class correlation coefficient for quantitative answers is detailed in Table 2. 
Values were significant for questions 15 (from WHODAS II) and 18 (from MIDAS) (Table 3).  
 
Table 2 Test–retest reliability with percentage agreement and kappa values  
%  Kappa  P value  
Agreement   for 
kappa 
No change expected  79.12–98.90  0.86–0.99  \0.0001  
Change unlikely  79.12–98.90  0.68–0.99  \0.0001  
±1 unit change expected  90.11–96.70  0.45–0.92  \0.0001  
±3 unit change expected  72.53–84.62  0.45  \0.0001  
Change likely  54.95–89.01  0.23–0.77  \0.0001  
 
Construct validity  
The mean frequency of headache days was significantly different between the three samples (Table 5). While few 
subjects had high headache frequency in the primary care and general population samples, a large proportion (45% 
of subjects) in the pain clinic sample had C15 headache days per month. However, there was no difference between 
the three samples in terms of average disability attributed to headaches (MIDAS total score) or of depression (as 
measured by PHQ9). The mean scores of WHODASII, MIDAS and PHQ9 were not different between the three 
samples (Table 6) except for a significant pair-wise difference between the pain clinic and the general population 
sample with the MIDAS total score (P \ 0.05) (Table 4).  
A subanalysis was carried-out after omitting patients (n = 71) with headache from the general population  
Table 3 Test–retest reliability with McNemar’s coefficient for 2 9 2 tables, Bowker’s coefficient for more than 2 classes variables and 
intraclass correlation for continuous variables  
Statistic  P value 
McNemar’s coefficient  0.11–3.57  0.74–0.06 
Bowker’s coefficient  0.00–10.07  0.03–1.00 
Intraclass correlation  0.79–0.99  0.04–0.92 
 
Raw  Standardized 
ID Migraine ScreenerTM  0.26  0.26  
WHODAS II questionnaire  0.80  0.91  
MIDAS questionnaire  0.68  0.74  
PHQ-9 questionnaire  0.85  0.84  
 
sample in order to better discriminate WHODASII, MIDAS and PHQ9 values between levels of headaches. The 
remaining general population sample (n = 22) was assumed completely healthy while the pain clinic sample was 
supposed to be the most affected group. Results showed a clear trend (P = 0.06) for the mean number of days with 
headaches and the presence of depressive disorder (P = 0.09). A highly significant difference was observed between 
the general population sample, the pain clinic and the primary care sample for MIDAS scores (P value = 0.0005) but 
not for the PHQ9 depressive disorder estimate (Table 5).  
The mean WHODASII score did not show any significant difference in this subanalysis while for MIDAS and 
PHQ9, total scores were significantly different (Table 6).  
When further analysing pair-wise relationships between the three samples, differences (P \ 0.05) were observed 
between the MIDAS score of the pain clinic sample and the general population sample when including all subjects, 
and also between the PHQ9 scores of the primary care and the general population sample (Table 6) when excluding 
incompletely healthy subjects from the general population sample.  
Internal consistency/content  
The standardized values of the Cronbach’s alpha to test the consistency of (ID, WHODASII, MIDAS and PH9 tested 
in the new questionnaire were 0.26, 0.91, 0.74 and 0.84, respectively. Questions categorized by the amount of change 
expected and compared between the test and the retest time to assess the internal consistency showed a 80– 100% 
agreement except for open questions where more than 70% change was observed (Electronic supplementary 
material).  
Discussion  
We described the development and methodological testing of a self-reporting questionnaire to evaluate the burden of 
migraine in the general population.  
Completion rates for each question were generally good with the vast majority between 60 and 90%. A small 
number  
Table 5 Construct validity for frequency of headaches, MIDAS, and PH9 categorical scores  
Whole population sample Healthy subjects  
Primary care  Pain clinic  General 
populatiosample 
nAll  Chi 
square  
General 
populatiosample  
nAll  Chi 
Square 
N mean (days/month of headaches)         
Less than 1 day  0 (0%)  0 (0%)  2 (2.15%)  2   1 (4.55%)  1   
1–3 days  5 (29.41%)  6 (30%)  20 (21.51%)  31   7 (31.82%)  18  
4–9 days  6 (35.29%)  2 (10%)  42 (45.16%)  50   9 (40.91%)  17  
10–14 days  3 (17.65%)  3 (15%)  18 (19.35%)  24   4 (18.18%)  10  
[15 days  3 (17.65%)  9 (45%)  11 (11.83%)  23   1 (4.55%)  13  
Total  17 (13.08%)  
20 
(15.38%)  93 (71.54%)  130 0.0238 22 (37.29%)  59 0.0629 
MIDAS score          
Minimal or infrequent 
disability  3 (23.08%)  4 (23.53%)  14 (19.44%)  21  
 9 (47.37%)  16  
Mild or infrequent disability  0 (0%)  0 (0%)  10 (13.89%)  10   5 (26.32%)  5   
Moderate disability  6 (46.15%)  2 (11.76%)  18 (25%)  26   4 (21.05%)  12  
Severe disability  4 (30.77%)  11 (64.71%)  30 (41.67%)  45  
 1 (5.26%)  16  
Total  13 (12.75%)  
17 
(16.67%)  72 (70.59%)  102 0.159  19 (38.78%)  49 0.0005 
Depressive disorder          
No  14 (82.35%)  17 (85%)  86 (92.47%)  117 
 22 (100%)  53  
Yes  3 (17.65%)  3 (15%)  7 (7.53%)  13   0 (0%)  6   
Total  17 (13.08%)  
20 
(15.38%)  93 (71.54%)  130 0.3179 22 (37.29%)  59 0.0977 
 
Headache days, the MIDAS score as a measure of disability and the presence of depression are 
detailed for the different samples of participants according to their origin. On the right hand side 
of the table, the subset of healthy participants (without headache) in the generation population 
sample, is detailed  
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General population sample Without unhealthy subjects  
 N  Mean  SD  P value  N  Mean  SD  P value 
WHODAS-II score12          
Primary care  13  25.85  15.15  0.5752  13  25.85  15.2  0.3015  
Pain clinic  15  21.3  18.42   15  21.3  18.4   
General population sample  84  24.14  15.09   21  17.59  12.8   
MIDAS score          
Primary care  13  22.92  22.73  0.2588*  13  22.92  22.7  0.0039* 
Pain clinic  17  38.47  33.87   17  38.47  33.9   
General population sample  72  22.71  20.84   19  7.37  7.11   
Score PHQ-9          
Primary care  17  9.24  4.51  0.219  17  9.24  4.51  0.0049** 
Pain clinic  20  8.1  5.62   20  8.1  5.62   
General population sample  93  7.53  4.59   22  4.95  2.57   
 
* Significant pairwise difference between pain clinic and general pop at the 5% level (Tukey 
post-hoc ANOVA tests)  
** Significant pairwise difference between primary care and general pop at the 5% level (Tukey 
post-hoc ANOVA tests)  
of questions showed low completion rates which can be explained by the fact that they were part of multiple-choice 
questions. Some other questions did not have to be answered in all participants since they applied only to subgroups. 
Questions from WHODAS II and PHQ9 showed both, good completion rates, and good reliability. For 
methodological purposes, we had defined the amount of change expected for each question before administering the 
questionnaire. Questions, where a change had been expected, actually showed higher amounts of change and lower 
reliability. This means, that these items were used in an appropriate way and that they can be used as part of a 
questionnaire on the impact and burden of migraine and headaches. The question ‘‘Feeling tired or having little 
energy’’ from PHQ9 was found to have little re-test reliability at 1 month interval which can be explained by the 
transient character of this item.  
Internal consistency was evaluated independently for each scale tested within in the questionnaire. It was found to 
be excellent for the MIDAS and somewhat smaller for questions from WHODASII and PHQ9.  
Construct validity was found to be acceptable when samples were adequately chosen to discriminate between 
levels of headache. However, questions from WHODAS showed a poor discrimination between headache patients 
and the general population. This can be explained by the fact that this tool is not specifically designed for headache 
sufferers. The headache specific MIDAS, as expected, showed good discriminative power.  
Disease management  
Regarding questions on disease management, agreement ranged from 77 to 98% (except for multiple-choice 
questions). Kappa coefficient ranged from 0.68 (0.62 with multiple-choice questions) to 1.00 which indicates good 
agreement between the two steps.  
The majority of the questions about private and social influence were of the multiple-choice type and scored 
poorly in terms of percentage agreement (10–30%), but had a good retest reliability (kappa coefficients ranging from  
0.52 to 0.97). These questions were therefore stable with time and could be used in a large study with a period of 
recruitment lasting a few months.  
Changes brought to the final questionnaire  
In the disease management part, two questions on medical doctor consultations were merged into one question 
allowing a better completion.  
In one question on the temporal relation between headache and other problems, in addition to ‘‘before,’’ and 
‘‘after’’ a third item ‘‘during’’ was added.  
Conclusions  
A new questionnaire, BURMIG, was developed with the aim to estimate the burden of migraine. It uses established 
and previously validated items for diagnosis and to measure disability and depression. Questions related to disease 
management and the influence on daily living were added. The resulting questionnaire was tested in a sample in the 
Grand Duchy of Luxembourg. Reliability and consistency of BURMIG were found to be comparable to previously 
published questionnaires. Therefore, this tool is suitable to study larger populations of headache patients.  
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